[go: up one dir, main page]

WO2013111014A3 - Methods and compositions for treating neuron loss in inflammatory bowel disease - Google Patents

Methods and compositions for treating neuron loss in inflammatory bowel disease Download PDF

Info

Publication number
WO2013111014A3
WO2013111014A3 PCT/IB2013/000463 IB2013000463W WO2013111014A3 WO 2013111014 A3 WO2013111014 A3 WO 2013111014A3 IB 2013000463 W IB2013000463 W IB 2013000463W WO 2013111014 A3 WO2013111014 A3 WO 2013111014A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
compositions
methods
bowel disease
neuron loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/000463
Other languages
French (fr)
Other versions
WO2013111014A2 (en
Inventor
Brian D. GULBRANSEN
Keith A. SHARKEY
Roger J. THOMPSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
Original Assignee
UTI LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP filed Critical UTI LP
Publication of WO2013111014A2 publication Critical patent/WO2013111014A2/en
Publication of WO2013111014A3 publication Critical patent/WO2013111014A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for the treatment of neuronal loss in inflammatory bowel disorders (e.g., Crohn's disease or ulcerative colitis) comprising inhibition of pannexin-1 in a subject.
PCT/IB2013/000463 2012-01-25 2013-01-25 Methods and compositions for treating neuron loss in inflammatory bowel disease Ceased WO2013111014A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261590530P 2012-01-25 2012-01-25
US61/590,530 2012-01-25

Publications (2)

Publication Number Publication Date
WO2013111014A2 WO2013111014A2 (en) 2013-08-01
WO2013111014A3 true WO2013111014A3 (en) 2013-10-31

Family

ID=48874023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/000463 Ceased WO2013111014A2 (en) 2012-01-25 2013-01-25 Methods and compositions for treating neuron loss in inflammatory bowel disease

Country Status (1)

Country Link
WO (1) WO2013111014A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2023143513A1 (en) * 2022-01-26 2023-08-03 羽晓瑜 Polypeptide compound and use therefor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEKENI, F. B. ET AL.: "Pannexin 1 channels mediate `find-me' signal release and membrane permeability during apoptosis", NATURE, vol. 467, October 2010 (2010-10-01), pages 863 - 867 *
GULBRANSEN, B. D. ET AL.: "Activation of neuronal P2X7 receptor-Pannexin-1 mediates death of enteric neurons during colitis", NATURE MED., vol. 18, October 2012 (2012-10-01), pages 600 - 604 *
SILVERMAN, W. R ET AL.: "The pannexin 1 channel activates the inflammasome in neurons and astrocyrtes", J. BIOL. CHEM., vol. 284, July 2009 (2009-07-01), pages 18143 - 18151 *
SRIDHARAN, M. ET AL.: "Pannexin 1 is the conduit for low oxygen tension- induced ATP release from human erythrocytes", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 299, October 2010 (2010-10-01), pages H1146 - H1152 *

Also Published As

Publication number Publication date
WO2013111014A2 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
IL276153B (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency .
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
IL258846A (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
WO2013169704A3 (en) TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2014055996A3 (en) Rho kinase inhibitors
MX2014010455A (en) Methods and compositions for treating huntington's disease.
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
HK1249508A1 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
MX2015015784A (en) Methods for diagnosing and treating inflammatory bowel disease.
PL3242957T3 (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
WO2015143447A3 (en) Methods for treating neurological disorders
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
PL3442547T3 (en) Lactobacillus reuteri mm4-1a for use in the treatment or prevention of autism spectrum disorders
WO2017044807A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP2869819A4 (en) Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
WO2010129347A3 (en) Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
SI3153511T1 (en) 2-acylaminothiazole derivative for use in the prevention or treatment of bladder/urinary tract diseases
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
EP3310377A4 (en) Method of treating crohn's disease
HK1214517A1 (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
WO2013111014A3 (en) Methods and compositions for treating neuron loss in inflammatory bowel disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13741179

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13741179

Country of ref document: EP

Kind code of ref document: A2